Results from the phase 3 trial used for Zejula’s approval show median progression-free survival with Zejula was 21 months in BRCA-mutated patients compared with 5.5 months for placebo.
In the PRIMA trial, Zejula (niraparib) improved progression-free survival when used as a maintenance ... Moreover, despite high response rates to platinum-based chemotherapy in the second-line ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback